Bladder Cancer

Later-Line Treatments for Metastatic Urothelial Carcinoma of the Bladder

Later-Line Treatments for Metastatic Urothelial Carcinoma of the Bladder

By

Researchers propose a treatment algorithm to clarify treatment options beyond the first line for metastatic urothelial carcinoma of the bladder.

Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer

Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer

By

BCG shortages did not appear to influence the incidence of radical cystectomy, but evidence of drug rationing was revealed.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

Stromal Cells Found to Act as Tumor Bodyguards in Bladder Cancer

Stromal Cells Found to Act as Tumor Bodyguards in Bladder Cancer

By

Gene expression of a biomarker linked to malignancies, found in stromal cells surrounding a tumor — not the tumor cells themselves — appears to prevent the action of checkpoint blockade.

Neoadjuvant Chemotherapy Before Radical Cystectomy May Improve Outcomes in Bladder Cancer

Neoadjuvant Chemotherapy Before Radical Cystectomy May Improve Outcomes in Bladder Cancer

By

Researchers assess the outcomes of 5517 patients with bladder cancer who underwent radical cystectomy with or without neoadjuvant radiotherapy or chemotherapy.

Neoadjuvant ddMVAC May Lead to Improved Treatment Response in Bladder Cancer

Neoadjuvant ddMVAC May Lead to Improved Treatment Response in Bladder Cancer

By

Previous studies showed that ddMVAC is well tolerated, but how it compares with gemcitabine plus cisplatin in regard to cancer control and survival outcomes requires further investigation.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Immediate Instillation of Mitomycin C Post-TURBT May Benefit All Patients with Bladder Cancer

Immediate Instillation of Mitomycin C Post-TURBT May Benefit All Patients with Bladder Cancer

By

A reanalysis suggested that an instillation of chemotherapy immediately after surgery may benefit all patients with non-muscle-invasive bladder cancer.

Approximately Two-Thirds of Patients With Stage IV Bladder Cancer Remain Untreated

Approximately Two-Thirds of Patients With Stage IV Bladder Cancer Remain Untreated

By

Patients in the SEER-Medicare database with stage IV bladder cancer were found to be less likely to receive chemotherapy than similar cohorts in earlier studies.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Robot-Assisted Cystectomy May Lead to Good Surgical, Oncologic Outcomes in Bladder Cancer

Robot-Assisted Cystectomy May Lead to Good Surgical, Oncologic Outcomes in Bladder Cancer

By

With the advent of minimally invasive surgery programs, robotic-assisted radical cystectomy is becoming a point of interest for bladder cancer.

Factors Associated With Locoregional Recurrence in Muscle-Invasive Bladder Cancer

Factors Associated With Locoregional Recurrence in Muscle-Invasive Bladder Cancer

By

A better understanding of the factors associated with locoregional recurrence and focused adjuvant therapeutic strategies may lead to enhanced oncologic outcomes.

Bladder Cancer Survival Better Among Married Patients

Bladder Cancer Survival Better Among Married Patients

By

Widowed patients with bladder urothelial carcinoma have the worst 5-year cancer-specific survival rates among unmarried patients.

Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer

Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer

By

Evidence for the impact of obesity on outcomes for bladder cancer have been conflicting and require further study.

Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

By

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

By

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Trimodal Therapy May Lead to Reduced Survival, Cost-Effectiveness in Bladder Cancer

Trimodal Therapy May Lead to Reduced Survival, Cost-Effectiveness in Bladder Cancer

By

Current guidelines recommend that patients with bladder cancer undergo radical cystectomy, but concerns with morbidity and mortality have led to a reemergence of trimodal "bladder-sparing" therapy.

Adding Gemcitabine at the Time of Resection Reduces Recurrence, Cost in Early-Stage Bladder Cancer

Adding Gemcitabine at the Time of Resection Reduces Recurrence, Cost in Early-Stage Bladder Cancer

By

Though early-stage bladder cancer is infrequently fatal, the decrease in recurrence rates has a meaningful impact on the quality of life for patients as well as treatment costs.

<i>ARID1A</i> Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

By

New findings bolster the case for the predictive utility of ARID1A mutations.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

By

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Novel FGFR3 Inhibitor May Be a New Treatment Option for Metastatic Urothelial Carcinoma

Novel FGFR3 Inhibitor May Be a New Treatment Option for Metastatic Urothelial Carcinoma

By

Previous early-phase clinical studies have demonstrated that BGJ398 was active and well tolerated in a variety of FGFR-altered cancers.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Active Surveillance After Complete Response to Chemotherapy May Be Effective in Bladder Cancer

Active Surveillance After Complete Response to Chemotherapy May Be Effective in Bladder Cancer

By

Many patients are cured of all disease (pT0) post-chemotherapy and may be able to defer invasive surgery if properly identified.

Postresection intravesical instillation of gemcitabine decreases non-muscle-invasive urothelial cancer recurrence

In this randomized controlled trial, instilling postresection chemotherapy, specifically gemcitabine, was found to decrease tumor recurrence in non-muscle-invasive urothelial cancer when compared to saline treatment as a placebo.

Bladder Cancer, UTUC More Common in Kidney Transplant Recipients

Bladder Cancer, UTUC More Common in Kidney Transplant Recipients

By

A study found that bladder cancer and UTUC occurred in 122.22 and 113.97 per 100,000 persons per year, respectively, among kidney transplant recipients.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Neoadjuvant Dose-Dense Gemcitabine, Cisplatin May Be an Ideal Regimen in Bladder Cancer

Neoadjuvant Dose-Dense Gemcitabine, Cisplatin May Be an Ideal Regimen in Bladder Cancer

By

Various aspects of optimal treatment, such as optimal dose, drug combination, number of cycles, and duration of therapy have yet to be clearly defined for patients with bladder cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs